BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:34 PM
 | 
Feb 04, 2008
 |  BC Extra  |  Top Story

Amgen, Takeda in broad Japanese deal

Takeda (Tokyo:4502) licensed exclusive, Japanese rights to up to 13 compounds from Amgen (NASDAQ:AMGN) and agreed to acquire Amgen K.K., Amgen's Japanese subsidiary, for an undisclosed amount. The deal includes Amgen's motesanib, which the companies partnered to develop and commercialize worldwide. Amgen will receive...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >